Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

20151,539 citationsJournal Articlebronze Open Access

Authors

Jan A. Burger · The University of Texas MD Anderson Cancer Center

Alessandra Tedeschi · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Paul M. Barr · University of Rochester

Tadeusz Robak · Medical University of Lodz

Carolyn Owen

Paolo Ghia · Vita-Salute San Raffaele University

Osnat Bairey · Rabin Medical Center

Abstract

Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables. (Funded by Pharmacyclics and others; RESONATE-2 ClinicalTrials.gov number, NCT01722487.).

Topics & Keywords

Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 25, pp. 2425-2437

DOI: 10.1056/nejmoa1509388

Field-Weighted Citation Impact: 78.37